[Form 4] MiNK Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

MiNK Therapeutics insider grant to director Brian Corvese: The filing reports a stock option grant awarding the Reporting Person the right to buy 3,225 shares of MiNK Therapeutics common stock at an exercise price of $15.36 per share. The transaction date is listed as 09/09/2025 and the option shows an expiration date of 09/09/2035 in the table. The form states the option "vests in full on the one-year anniversary of the date of grant" provided the reporting person continues to serve on the company’s board through that date. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/11/2025.

Positive

• Issuance aligns director incentives with shareholders via equity rather than cash compensation.
• Clear vesting condition (vests in full on the one-year anniversary) ties award to continued board service.
• Full disclosure of key terms (number of options, exercise price, transaction date, expiration) is provided on Form 4.

Negative

• None.

Insights

Securities Analyst

TL;DR: A routine director option grant: modest share amount, time-limited exercise window, standard service-based vesting.

The reported grant of 3,225 options at $15.36 appears to be a typical non-employee director equity award disclosed on Form 4. The stated expiration of 09/09/2035 provides a ten-year exercise window from the reported transaction date. The explicit vesting language—"vests in full on the one-year anniversary of the date of grant"—ties realization to continued board service, aligning executive incentives with shareholder interests. From a disclosure perspective, the form supplies the core terms investors need to track potential dilution and insider alignment.

Corporate Governance Specialist

TL;DR: Governance-standard grant with service-based vesting; disclosure is concise and transparent.

The filing documents a director compensation action rather than an employment change or material corporate event. The one-year cliff vesting is a common governance practice for non-employee director awards and reduces immediate selling pressure while incentivizing continued service. The amount—3,225 shares—is small relative to typical public-company float sizes; the Form 4 includes required details such as price, grant date, and expiration, supporting straightforward investor monitoring of insider holdings and potential future exercises.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Corvese Brian

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.36	09/09/2025		A		3,225		(1)	09/09/2035	Common Stock	3,225	$0	3,225	D

Explanation of Responses:

1. The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.

	By: /s/ Christine Klaskin, Attorney-in-Fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did INKT director Brian Corvese receive according to this Form 4?

The Form 4 reports a grant of 3,225 stock options with an exercise price of $15.36 per share, dated 09/09/2025.

When do the options vest and when do they expire?

The filing states the option "vests in full on the one-year anniversary of the date of grant" and the table lists an expiration date of 09/09/2035.

Does the Form 4 show whether the transaction was a purchase or grant?

The transaction code is "A", indicating acquisition; the form shows these options were acquired on the stated transaction date.

Who signed the Form 4 and when was it filed?

The Form 4 was signed by an attorney-in-fact, Christine Klaskin, on 09/11/2025.